Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
about
Molecular testing to optimize therapeutic decision making in advanced colorectal cancerClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerTreatment Individualization in Colorectal CancerDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerBRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Meeting An Unmet Need in Metastatic Colorectal Carcinoma with RegorafenibImmunotherapy in human colorectal cancer: Challenges and prospectiveMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerClinical Application of Targeted Next Generation Sequencing for Colorectal CancersExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachYttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerEpidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysPredictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasisExpanded RAS: refining the patient populationCharacterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumabRetreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseEastern Canadian Gastrointestinal Cancer Consensus Conference 2014.CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to PracticeA rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centresPerformance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients.In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.RAS testing in metastatic colorectal cancer: advances in EuropeNovel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer
P2860
Q26749012-2C7B9769-E1F7-4F80-BE62-F12CF98B2070Q26769958-A5010A45-E66C-4CC7-A4A6-7E46DE88D1E0Q26776215-0587A9B4-490F-48F0-8890-EF886C2906D8Q26781362-BC6E7B24-A4C5-4454-93EF-437DD4E031F7Q26796348-1755163A-93C4-4397-97F4-7E719D54E872Q27027648-D4C18DEB-7D1D-4747-AE86-0882BF152C45Q27853371-D5EB2A11-9A9C-4BC3-80DA-6CF882B3EE5FQ28068616-C200208C-9C0B-4C70-A863-1AC848C0FC6FQ28068788-B461DCB5-A7C8-4446-B4EF-D6BA220FB189Q28070038-97304CA8-BDFF-477E-AD16-35E712E77555Q28071772-9DA7CC8F-BF9D-4C7F-8646-985145980D7CQ28076490-E9CD1A42-A9FD-4F43-BF74-3CE1CE55687EQ28077199-927E20A0-8B1B-45F4-9D5F-1BD78A1572B4Q28087333-E3E27069-57C9-404C-A356-DD7F377FAF21Q28647615-AA209213-81AB-42CC-8656-A446527AD3CDQ30353464-4FD8087E-E525-481D-942C-39F5D32E0D64Q30967175-2FDEE028-390F-4805-8B0F-0F82EA2B1AC3Q30972278-7A9BB87C-981C-4198-A391-EFA76FEB4D0AQ33624491-75F1A9F5-9AB8-4973-8304-C303B0550413Q33737298-5CA29494-9463-40A6-8131-A535B5870D6BQ33914190-B80C6983-8F65-490A-AA9F-2B432E3A41DEQ35102475-DA4C81CD-38C1-43F6-BE26-3A72C65EC6EBQ35218647-1C0F8A7C-C587-47F8-962D-F37D18314456Q35491379-A42C2C6E-9428-43B7-99DA-FBE40F25CEE6Q35810693-CCAECD0D-8F6D-4DA9-999C-5941DDF50624Q35934322-0082E42D-7A15-4841-A0C1-458AF9638E64Q35962454-8BDB0B97-075F-496B-8A5D-A209B592EF5BQ36093324-13205E98-9C28-494D-BF46-EDED4C3CF264Q36148358-84D0844C-BE7D-4D3D-9426-323A6029BB42Q36175288-F2012C1F-69D5-44FE-9490-DE58D362ECB8Q36201032-620F4C0A-04BF-4EB7-96A4-74F6BCA8F449Q36244599-DB1A76C1-B250-44F2-8972-C1062B7204B4Q36287075-ED6CF92F-B23A-41DC-A5B5-EAF6C8DAE316Q36289908-12ABDEF7-9967-4ECA-BC0A-21EE06358E6AQ36310845-96847CB1-6317-4794-8D5A-7DFD18EE55A0Q36400301-75DBB081-B5FC-4766-BE3E-591520D7FD32Q36472281-88F1C31F-7CD6-4AE7-9794-18766B04995BQ36544641-71B66FD2-01AD-4A0B-9DC2-30A0A6717E5AQ36795904-95BF77C8-51A2-4A4F-B7B4-9A2DA4B2EA4DQ36932799-F7F1EE38-557E-4F28-B6B7-EF5B28F2EC5A
P2860
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Extended RAS mutations and ant ...... randomized, controlled trials.
@en
type
label
Extended RAS mutations and ant ...... randomized, controlled trials.
@en
prefLabel
Extended RAS mutations and ant ...... randomized, controlled trials.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Extended RAS mutations and ant ...... randomized, controlled trials.
@en
P2093
C S Karapetis
G Kichenadasse
M J Sorich
R A McKinnon
P2860
P356
10.1093/ANNONC/MDU378
P50
P577
2014-08-12T00:00:00Z